ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31

Oruka Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$74.48+2.55 (+3.55%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Oruka Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31	Q4 2018 2018-12-31	Q3 2018 2018-09-30	Q2 2018 2018-06-30	Q1 2018 2018-03-31	Q4 2017 2017-12-31	Q3 2017 2017-09-30	Q2 2017 2017-06-30	Q1 2017 2017-03-31	Q4 2016 2016-12-31	Q3 2016 2016-09-30	Q2 2016 2016-06-30	Q1 2016 2016-03-31	Q4 2015 2015-12-31
Depreciation & Amortization	–	–	–	–	–	–	–	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.01
Stock-Based Compensation	7.28	6.97	4.12	10	5.08	4.88	9.00	0.68	0.11	0.14	0.15	0.19	0.20	0.12	0.10	0.17	0.17	0.12	0.10	0.13	0.14	0.02	0.02	0.03	0.03	0.05	0.05	0.06	0.06	0.06	0.10	0.12	0.12	0.12	0.10	-0.03	0.27	0.18	0.16	0.15
Change in Accounts Payable	–	–	–	–	–	–	–	0.04	0.17	0.04	0.08	-0.13	0.03	-0.26	-0.52	0.10	-0.10	-0.01	-1.07	0.61	0.06	1.02	-0.29	0.28	-0.08	-0.01	0.00	0.01	-0.19	-0.20	-0.01	-0.61	0.17	0.09	-0.23	0.19	0.26	0.01	0.38	-0.26
Operating Cash Flow	-33	-24	-23	-22	-23	-21	–	-2.63	-1.53	-1.06	-1.67	-0.69	-1.60	-1.49	-2.50	-2.62	-4.30	-4.95	-4.87	-3.72	-5.23	-3.00	-1.69	-1.16	-0.89	-1.19	-1.57	-1.34	-1.58	-2.25	-3.07	-4.20	-3.97	-4.96	-4.34	-3.84	-3.74	-3.53	-3.88	-2.62
Capital Expenditures	0	-0.07	-0.06	-0.10	-0.03	-0.01	–	–	–	–	–	–	–	0	0	0	0.00	-0.01	-0.01	-0.02	-0.01	-0.01	0.00	0.00	–	–	–	0	0.00	0	0.00	0.00	0	–	–	0.00	-0.01	0.00	0.00	0.00
Purchase of Investments	-491	-91	-101	-268	-108	-44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	-3.43	-0.50	-1.54	0	-3.04	-12	-5.20	–
Sale & Maturity of Investments	80	76	79	145	113	87	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	-411	-14	-22	-122	4.86	43	–	0	0	–	–	0	0	0	0	0	0.00	-0.01	-0.01	-0.02	-0.01	-0.01	0.00	0.00	–	–	–	0	0.00	0	3.05	4.75	-0.93	6.10	3.01	3.15	-2.55	-12	-5.20	0.00
Stock Issued	4.37	1.70	0.56	0	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	24	1.25	–	0	0.76	3.44	3.08	0	0	0	3.53	0.04	4.23	2.07	0.21	–	–	–	–	0
Financing Cash Flow	663	41	0.30	170	–	–	–	0.01	0	–	–	0	0	–	–	–	–	0	0	0	23	0.98	–	-0.12	0.57	3.15	2.96	-0.11	0	-0.21	3.42	0.01	3.95	1.79	0.11	–	–	–	–	-0.06
Net Change in Cash	–	–	–	–	–	–	–	-2.62	-1.53	-1.06	-1.67	-0.69	-1.60	-1.49	-2.50	-2.62	-4.30	-4.95	-4.88	-3.74	18	-2.02	-1.69	-1.28	-0.32	1.96	1.40	-1.45	-1.58	-2.46	3.39	0.56	-0.96	–	–	–	–	–	–	–
Free Cash Flow	-33	-24	-23	-22	-23	-21	–	–	–	–	–	–	–	-1.49	-2.50	-2.62	-4.30	-4.95	-4.88	-3.74	-5.23	-3.01	-1.69	-1.16	–	–	–	-1.34	-1.58	-2.25	-3.07	-4.20	-3.97	–	–	-3.85	-3.74	-3.53	-3.88	-2.62
Interest Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	–	0.00	0.00	–	–	0.00	0	–	–	0	0.00	–	–	–	–	–	–	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -24.7%

Financial strength

Current ratio: 38.51
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1168.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –